ANG: A Potential Drug Target for Chronic Inflammation (G283)

Target Name: ANG

NCBI ID: G283

Content of Review Report on ANG Target / Biomarker

ANG

ANG: A Potential Drug Target for Chronic Inflammation

ANG (Angiogenin) is a protein that is expressed in the endothelial cells of the body, which line the blood vessels. It is a potent pro-inflammatory cytokine that has been shown to play a role in the development and progression of a number of diseases , including cancer, heart disease, and diabetes.

Recently, ANG has gained significant attention as a potential drug target or biomarker. Its ability to stimulate the production of pro-inflammatory cytokines has made it an attractive target for researchers looking for new treatments for inflammatory diseases.

One of the key reasons for ANG's potential as a drug target is its ability to induce the production of pro-inflammatory cytokines. These cytokines, such as TNF-alpha, IL-1, and IL-6, are involved in the recruitment of immune cells to the site of inflammation and are thought to play a key role in the development of many diseases.

In addition to its ability to induce the production of pro-inflammatory cytokines, ANG has also been shown to play a role in the regulation of immune cell function. Studies have shown that ANG can inhibit the activity of T-cells, which are a key component of the immune system, and can also inhibit the production of antibodies.

These findings have led some researchers to speculate that ANG may be a useful drug target for diseases that are characterized by chronic inflammation, such as cancer, heart disease, and diabetes. By targeting ANG with drugs that can inhibit its activity, researchers may be able to reduce the production of pro-inflammatory cytokines and improve the immune function of the body.

Another potential use of ANG as a drug target is its ability to serve as a biomarker for the diagnosis and monitoring of certain diseases. The production of pro-inflammatory cytokines is often an indicator of inflammation in the body, and ANG levels have been shown to be elevated in a number of diseases, including cancer, heart disease, and diabetes.

By using ANG as a biomarker, researchers may be able to monitor the effectiveness of new treatments and make early adjustments to their treatment plans. For example, if an individual's ANG levels are elevated, it may be a sign that their treatment is having the desired effect and that they should continue to receive the treatment.

In addition to its potential as a drug target and biomarker, ANG has also been shown to have a number of potential therapeutic applications. For example, studies have shown that ANG can be used to treat certain types of cancer by inhibiting the production of pro- inflammatory cytokines.

In addition, ANG has also been shown to have a potential therapeutic application for treating other diseases that are characterized by chronic inflammation, such as rheumatoid arthritis and Crohn's disease. By using ANG as an anti-inflammatory drug, researchers may be able to reduce the produce pro-inflammatory cytokines and improve the immune function of the body.

Overall, ANG is a protein that has significant potential as a drug target or biomarker for a number of diseases. Its ability to stimulate the production of pro-inflammatory cytokines and its potential therapeutic applications make it an attractive target for researchers looking for new treatments for inflammatory diseases.

Protein Name: Angiogenin

Functions: Ribonuclease that cleaves tRNA within anticodon loops to produce tRNA-derived stress-induced fragments (tiRNAs) which inhibit protein synthesis and triggers the assembly of stress granules (SGs) (PubMed:1400510, PubMed:21855800). Binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus (PubMed:8127865). Stimulates ribosomal RNA synthesis including that containing the initiation site sequences of 45S rRNA (PubMed:12051708). Angiogenin induces vascularization of normal and malignant tissues (PubMed:19354288). Angiogenic activity is regulated by interaction with RNH1 in vivo (PubMed:19354288)

The "ANG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets